Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

Recruiting in Palo Alto (17 mi)

+23 other locations

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Veru Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer

Eligibility Criteria

Inclusion Criteria

Be over 18 years of age;

Be able to communicate effectively with the study personnel;

Have histologically confirmed prostate cancer;

Treatment Details

Interventions

• Placebo (Other)
• Veru-944 (Other)

Participant Groups

Group I: Veru-944 50 mg Experimental Treatment 1 Intervention

Veru-944 50 mg daily

Group II: Veru-944 10 mg Experimental Treatment 1 Intervention

Veru-944 10 mg daily

Group III: Placebo Placebo Group 1 Intervention

Placebo daily

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

First Urology Jeffersonville, IN

Advance Urology Elmont, NY

AccuMed Research Garden City, NY

Premier Medical Group of the Hudson Valley Poughkeepsie, NY

More Trial Locations

Who Is Running the Clinical Trial?

Veru Inc. Lead Sponsor

References